The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble (BMBL), which completed the year's largest deal so far, and Chinese cloud services provider Cloopen Group (RAAS), which bagged the biggest pop of 2021 to date. Bumble (BMBL) priced further...read more
Biophytis, a French Phase 2 biotech developing therapies for COVID-related complications and age-related diseases, raised $20 million by offering 1.2 million ADSs at $16.75, within the range of $15 to $18. The company is currently listed on the Euronext Growth Paris (ALBPS). Biophytis' lead candidate, Sarconeos (BIO101), is an orally administered small molecule...read more
Updated Monday, 2/8. The IPO market is buzzing with 15 IPOs slated to raise $4.0 billion in the week ahead, led by dating app Bumble’s billion-dollar offering. Bumble (BMBL) plans to raise $1.7 billion at a $7.5 billion market cap. The company operates the Bumble and Badoo apps, the world’s second and fourth highest grossing dating...read more
Biophytis, a French Phase 2 biotech developing therapies for COVID-related complications and age-related diseases, announced terms for its IPO on Tuesday. The company is currently listed on the Euronext Growth Paris (ALBPS). It previously filed to raise $15 million in the US in May 2019, but withdrew the following July. The Paris, France-based company plans to raise...read more
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
US IPO Weekly Recap: IPO frenzy brings the year’s largest deal and biggest pop in a 17 IPO week
The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble (BMBL), which completed the year's largest deal so far, and Chinese cloud services provider Cloopen Group (RAAS), which bagged the biggest pop of 2021 to date. Bumble (BMBL) priced further...read more
French biotech Biophytis prices US IPO at $16.75, within the range
Biophytis, a French Phase 2 biotech developing therapies for COVID-related complications and age-related diseases, raised $20 million by offering 1.2 million ADSs at $16.75, within the range of $15 to $18. The company is currently listed on the Euronext Growth Paris (ALBPS). Biophytis' lead candidate, Sarconeos (BIO101), is an orally administered small molecule...read more
US IPO Week Ahead: Bumble’s billion-dollar deal leads a buzzy 15 IPO week
Updated Monday, 2/8. The IPO market is buzzing with 15 IPOs slated to raise $4.0 billion in the week ahead, led by dating app Bumble’s billion-dollar offering. Bumble (BMBL) plans to raise $1.7 billion at a $7.5 billion market cap. The company operates the Bumble and Badoo apps, the world’s second and fourth highest grossing dating...read more
French biotech Biophytis sets terms for $20 million US IPO
Biophytis, a French Phase 2 biotech developing therapies for COVID-related complications and age-related diseases, announced terms for its IPO on Tuesday. The company is currently listed on the Euronext Growth Paris (ALBPS). It previously filed to raise $15 million in the US in May 2019, but withdrew the following July. The Paris, France-based company plans to raise...read more